A federal government proposal to save $590 million by 2030 by tightening the Research and Development Tax Incentive is set to go before the Senate this month, after passing the House of Representatives in late October. The changes, which would take effect from June 1, 2028, aim to restrict access to refundable tax offsets for small businesses after ten years in business (15 years for firms developing therapeutic goods) and prevent claims for activities that only indirectly support main R&D work.
The R&D Tax Incentive cost the federal budget A$4.3 billion in foregone revenue in 2024–25 alone and is claimed by more than 13,000 Australian companies, half of which are small businesses. If passed, the government’s proposed changes would be the most significant change to the scheme since it was introduced in 2011.
Under the plan, small businesses would no longer be able to access the generous refundable tax offset once they have been in business for ten years, or 15 years for firms developing therapeutic goods. At the same time, the government would lift the turnover threshold for the highest refundable rate from $20 million to $50 million, allowing more small firms to access it for longer.
However, companies would also be prevented from claiming tax breaks for activities that only indirectly support their core R&D work. For example, a company developing a new cancer treatment could claim the costs of experiments testing whether a new drug kills cancer cells, but may no longer be able to claim the costs of cleaning and maintaining laboratory equipment used in those experiments.
Startups with a long road to success would be most affected. The 15-year limit for therapeutic goods companies was a response to lobbying from the biotechnology industry, given the extended time needed to bring such products to market. While this longer timeframe has been welcomed, many startups, research organisations and politicians want the age limit scrapped entirely. Some Australian life science companies have said their tax offsets could be reduced by up to 60% if the changes pass.
Labor backbencher and former industry and science minister Ed Husic argued that Treasury and the Department of Finance “do not look at Australian R&D as an investment. They see it as a cost”. He added: “If we want the country to be stronger longer term […] in a changing world, we need to not only back our scientists and researchers; we absolutely have to back those startups, those early-stage companies, to make sure that they can succeed in the best possible way.”
Coalition MPs voted against the bill in the lower house and are unlikely to support it in the Senate. If so, the Greens’ votes could prove decisive. The Greens have signalled they will not support the changes unless large oil and gas producers are restricted from claiming hundreds of millions of dollars in tax offsets each year. If the government is willing to compromise with the Greens, the savings to revenue could be significant. Doing so would mean the government faced a backlash from oil and gas companies.
Another major point of contention is likely to be the ten-year age limit for most companies. If a limit is kept, it should arguably be increased to 15 years for consistency with other government proposals.
The changes aim to decrease the cost of the R&D incentive and make sure companies are not taking advantage of tax breaks without producing tangible benefits to Australia. The government needs to be wary of setting back Australian startup companies and homegrown innovation.
Analysis
Why This Matters
- The R&D Tax Incentive is a key driver of innovation for thousands of Australian small businesses and startups, and major changes could reduce funding for early-stage research at a time when Australia’s R&D spending lags the OECD average.
- The bill’s fate depends on negotiations with the Greens, which could lead to additional restrictions on oil and gas companies, shifting the savings target and political dynamics.
- Life science companies, which already face long development timelines, could see a significant reduction in tax offsets, potentially slowing medical and biotech innovation.
Background
The R&D Tax Incentive was introduced in 2011 to encourage Australian companies to invest in research and development. It provides a refundable tax offset for eligible R&D activities, particularly benefiting small businesses that may not have taxable income to offset. The federal government is under pressure to cut spending to help fight inflation, which has remained persistently high despite five interest rate hikes this year. Both business and government spending on R&D in Australia is much lower than the OECD average.
Key Perspectives
Federal Government: argues the changes will save $590 million by 2030 and ensure the incentive is not claimed for activities that do not produce tangible benefits, while making the highest refundable rate available to more young companies.
Startups, research organisations and some politicians: want the age limit scrapped altogether, arguing the ten-year cap will hurt companies with long paths to market and reduce innovation.
Coalition MPs: voted against the bill in the House of Representatives and are unlikely to support it in the Senate.
The Greens: have signalled they will not support the R&D tax changes unless large oil and gas producers are restricted from claiming hundreds of millions of dollars in tax offsets under the incentive each year.
Australian life science companies: say they might have tax offsets reduced by up to 60% if the changes pass.
Ed Husic (Labor backbencher, former industry and science minister): argued Treasury and the Department of Finance “do not look at Australian R&D as an investment. They see it as a cost,” and called for stronger backing of startups and early-stage companies.
What to Watch
- Whether the Greens secure restrictions on oil and gas producers in exchange for supporting the bill, and the resulting savings to revenue.
- The fate of the ten-year age limit: whether it is kept, increased to 15 years, or removed entirely.
- How the changes affect R&D investment by Australian startups and life science companies in the years after 2028.
Checked
12 claims in this story checked against 1 source: 10 supported.
Show each claim
- Partly supportedThe proposed overhaul could save $590 million.The Conversation – Articles (AU): “The federal government is now trying to change the tax break to save $590 million by 2030 .”
- SupportedThe proposal is due to go before the Senate this month.The Conversation – Articles (AU): “It’s due to go before the Senate this month.”
- Partly supportedStartups and life science firms are the groups most affected by the changes.The Conversation – Articles (AU): “Startup companies with a long road to success would be most affected by these proposed changes. ... Some Australian life science companies ... have said they might have tax offsets reduced by up to 60% if the changes pass.”
- SupportedThe bill passed the House of Representatives in late October.The Conversation – Articles (AU): “The bill containing the proposed R&D tax incentive changes passed the House of Representatives at the end of October.”
- SupportedThe changes would take effect from June 1, 2028, and limit small businesses’ access to the refundable offset after 10 years, or 15 years for firms developing therapeutic goods.The Conversation – Articles (AU): “All of the changes would begin from June 1 2028. ... stop small businesses accessing a generous refundable tax offset once they have been in business for ten years. For firms developing therapeutic goods, the limit is 15 years.”
- SupportedThe R&D Tax Incentive cost the federal budget A$4.3 billion in foregone revenue in 2024–25.The Conversation – Articles (AU): “That cost the federal budget A$4.3 billion in foregone revenue in 2024–25 alone.”
- SupportedMore than 13,000 Australian companies claim the incentive, half of them small businesses.The Conversation – Articles (AU): “Each year, more than 13,000 Australian companies – half of which are small businesses – claim a tax break for doing research and development work through the “R&D tax incentive”.”
- SupportedIf passed, the changes would be the most significant change to the scheme since its introduction in 2011.The Conversation – Articles (AU): “If it passes, it would be the most significant change to the incentive scheme since it was introduced in 2011.”
- SupportedThe plan would raise the turnover threshold for the highest refundable tax offset rate from $20 million to $50 million.The Conversation – Articles (AU): “Small firms would also be able to access the highest refundable tax offset rate for longer, by lifting the eligibility from companies with turnover of $20 million up to $50 million.”
- SupportedEd Husic said Treasury and the Department of Finance “do not look at Australian R&D as an investment. They see it as a cost”.The Conversation – Articles (AU): “Outspoken Labor backbencher and former industry and science minister Ed Husic recently argued Treasury and the Department of Finance “do not look at Australian R&D as an investment. They see it as a cost””
- SupportedEd Husic said: “If we want the country to be stronger longer term […] in a changing world, we need to not only back our scientists and researchers; we absolutely have to back those startups, those early-stage companies, to make sure that they can succeed in the best possible way.”The Conversation – Articles (AU): “If we want the country to be stronger longer term […] in a changing world, we need to not only back our scientists and researchers; we absolutely have to back those startups, those early-stage companies, to make sure that they can succeed in the best possible way.”
- SupportedSome Australian life science companies said their tax offsets could be reduced by up to 60% if the changes pass.The Conversation – Articles (AU): “Some Australian life science companies – doing work such as developing medicines, vaccines and medical technologies – have said they might have tax offsets reduced by up to 60% if the changes pass.”